Literature DB >> 20712765

Pathogenesis and management of iron toxicity in thalassemia.

Chaim Hershko1.   

Abstract

In thalassemia major, iron overload is the joint outcome of multiple blood transfusions and an inappropriately increased iron absorption associated with ineffective erythropoiesis. Threshold values for iron toxicity are a liver iron concentration exceeding 440 mmoles/g dry weight, serum ferritin >2500 ng/mL, DFO urinary iron excretion >20 mg/day, and transferrin saturation >75%. The outpouring of catabolic iron that exceeds the iron-carrying capacity of transferrin results in the emergence of non-transferrin-bound iron (NTBI). NTBI is cleared preferentially by the liver and myocardium at a rate exceeding 200 times that of transferrin iron. NTBI catalyzes the formation of free radicals, resulting in oxidative stress and damage to mitochondria, lysosomes, lipid membranes, proteins, and DNA. The long-term consequences of iron toxicity, including cirrhosis, myocardiopathy, and endocrine disorders, are preventable and mostly reversible by effective iron chelation therapy. Recent technologic advances in the documentation of organ-specific siderosis and the improved efficiency of iron chelating programs resulted in a spectacular improvement in the prevention of iron-induced end-organ failure and improved survival in thalassemic patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20712765     DOI: 10.1111/j.1749-6632.2010.05544.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  44 in total

1.  Detection of myocardial iron overload by two-dimensional speckle tracking in patients with beta-thalassaemia major: a combined echocardiographic and T2* segmental CMR study.

Authors:  Fausto Pizzino; Antonella Meloni; Anna Terrizzi; Tommaso Casini; Anna Spasiano; Carlo Cosmi; Massimo Allò; Concetta Zito; Scipione Carerj; Giovanni Donato Aquaro; Gianluca Di Bella; Alessia Pepe
Journal:  Int J Cardiovasc Imaging       Date:  2017-08-02       Impact factor: 2.357

2.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

3.  Intestinal brush-border Na+/H+ exchanger-3 drives H+-coupled iron absorption in the mouse.

Authors:  Ali Shawki; Melinda A Engevik; Robert S Kim; Patrick B Knight; Rusty A Baik; Sarah R Anthony; Roger T Worrell; Gary E Shull; Bryan Mackenzie
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-07       Impact factor: 4.052

Review 4.  Early detection of cardiac involvement in thalassemia: From bench to bedside perspective.

Authors:  Nut Koonrungsesomboon; Siriporn C Chattipakorn; Suthat Fucharoen; Nipon Chattipakorn
Journal:  World J Cardiol       Date:  2013-08-26

5.  Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.

Authors:  Robert W Grady; Renzo Galanello; Rachel E Randolph; Dorothy A Kleinert; Carlo Dessi; Patricia J Giardina
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 6.  Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.

Authors:  Richard Gordan; Suwakon Wongjaikam; Judith K Gwathmey; Nipon Chattipakorn; Siriporn C Chattipakorn; Lai-Hua Xie
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

7.  Ringed sideroblasts in β-thalassemia.

Authors:  Kim Cattivelli; Dean R Campagna; Klaus Schmitz-Abe; Matthew M Heeney; Hassan M Yaish; Amy E Caruso Brown; Susan Kearney; Kelly Walkovich; Kyriacos Markianos; Mark D Fleming; Ellis J Neufeld
Journal:  Pediatr Blood Cancer       Date:  2016-11-03       Impact factor: 3.167

8.  Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.

Authors:  Rebecca L C Adams; Robert J Bird
Journal:  Ther Adv Hematol       Date:  2013-04

9.  Pathophysiology and Clinical Manifestations of the β-Thalassemias.

Authors:  Arthur W Nienhuis; David G Nathan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 10.  H(+)-coupled divalent metal-ion transporter-1: functional properties, physiological roles and therapeutics.

Authors:  Ali Shawki; Patrick B Knight; Bryan D Maliken; Eric J Niespodzany; Bryan Mackenzie
Journal:  Curr Top Membr       Date:  2012       Impact factor: 3.049

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.